Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Feb;40(8):1393-1395.
doi: 10.1038/s41388-020-01611-6. Epub 2021 Jan 26.

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor

Joseph E Grossman  1 , Divya Vasudevan  1 , Cailin E Joyce  1 , Manuel Hildago  2
Affiliations
Editorial

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor

Joseph E Grossman et al. Oncogene. 2021 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

JEG is an employee of Agenus Inc. MH is the founder of Champions Oncology, Inc. and Nelum Oncology; a stockholder in Champions Oncology, Inc., Agenus, Nelum Oncology, BioOncotech, Inxmed and Pharmacyte; a grants/research support recipient from Bioline, Erytech, and BioExcell; an honorarium recipient from Agenus, InxMed, and Oncomatrix; and a royalty recipient from Myriad for PALB2 patent.

References

    1. Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. J Clin Oncol. 2019;37:2825–34. doi: 10.1200/JCO.19.00739. - DOI - PMC - PubMed
    1. Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;15:3005–3005. doi: 10.1200/jco.2014.32.15_suppl.3005. - DOI
    1. Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119:153–9. doi: 10.1038/s41416-018-0131-9. - DOI - PMC - PubMed
    1. Chung HC, Schellens JHM, Delord J-P, Perets R, Italiano A, Shapira-Frommer R, et al. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study. J Clin Oncol. 2018;36:5522–5522. doi: 10.1200/JCO.2018.36.15_suppl.5522. - DOI
    1. O’Malley DM, Oaknin A, Monk BJ, Leary A, Selle F, Alexandre J, et al. LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials. Ann Oncol. 2020;31:S1164–S1165. doi: 10.1016/j.annonc.2020.08.2264. - DOI

Publication types

MeSH terms